Biocartis

The firm said it plans to accelerate the expansion of its test menu through partnerships with pharma and biotech companies.

Qiagen believes the flexibility of the Stat-Dx platform for an evolving reimbursement landscape will set it apart from other similar commercial platforms.

Running on the Biocartis Idylla platform, Immunexpress' Septicyte test will detect sepsis in patients in as little as an hour.

Biocartis will help develop and commercialize Immunexpress' Septicyte test to run on the Idylla platform.

The companies are aiming to develop Idylla-based CDx biomarker tests for a compound Amgen is developing to treat solid tumors.

The companies are seeking to register Biocartis' Idylla RAS biomarker tests with the FDA as companion diagnostics for Amgen's Vectibix.

The firm said it raised €80 million to fund an expansion of, and new applications for, the Idylla test menu.

The tests were developed as part of a partnership with Merck KGaA, one of the manufacturers of the anti-EGFR therapy Erbitux.

Genomic Health will gain exclusive worldwide rights to develop and sell an IVD version of its Oncotype DX breast cancer test on Biocartis' Idylla platform.

The company is working to secure US pharmaceutical partners for its Idylla system and expects its US activities to begin driving growth by the end of 2017

Pages

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.